Gpc3 Gpc3 Gpc3-targeted Therapeutic Agent For Administration To Patients For Whom Gpc3-targeted Therapeutic Agent Therapy Is Effective

  • Published: Jan 10, 2017
  • Earliest Priority: May 08 2014
  • Family: 10
  • Cited Works: 8
  • Cited by: 0
  • Cites: 8
  • Sequences: 164
  • Additional Info: Cited Works Sequence
Full-text?

The full document isn't yet available to us from the patent office, but we've found a related patent (family member) to use for our images and PDF.

Abstract

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including measuring the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of an immunocyte or an expression level of a molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.


Claims

Information currently unavailable.

CPC Classifications
Family Member PDF
Family Member Preview
These are the images from a related family member, as the full document isn't yet available to us from the patent office.
Document History
  • Publication: Jan 10, 2017
  • Application: May 8, 2015
    KR KR 20167034321 A
  • Priority: May 8, 2015
    JP 2015002352 W
  • Priority: May 8, 2014
    US US 201461990238 P

Download Citation


Sign in to the Lens

Feedback